|
Gene: SPECC1L |
Gene summary for SPECC1L |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPECC1L | Gene ID | 23384 |
Gene name | sperm antigen with calponin homology and coiled-coil domains 1 like | |
Gene Alias | CYTSA | |
Cytomap | 22q11.23 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | B2RMV2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23384 | SPECC1L | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.20e-04 | 1.72e-01 | 0.0155 |
23384 | SPECC1L | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.06e-20 | 7.04e-01 | -0.1808 |
23384 | SPECC1L | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.12e-13 | 4.92e-01 | -0.0811 |
23384 | SPECC1L | HTA11_78_2000001011 | Human | Colorectum | AD | 1.26e-15 | 5.50e-01 | -0.1088 |
23384 | SPECC1L | HTA11_347_2000001011 | Human | Colorectum | AD | 1.29e-52 | 1.12e+00 | -0.1954 |
23384 | SPECC1L | HTA11_411_2000001011 | Human | Colorectum | SER | 1.97e-12 | 1.02e+00 | -0.2602 |
23384 | SPECC1L | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.44e-16 | 1.20e+00 | -0.2196 |
23384 | SPECC1L | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.15e-08 | 4.40e-01 | -0.1207 |
23384 | SPECC1L | HTA11_83_2000001011 | Human | Colorectum | SER | 5.34e-22 | 7.27e-01 | -0.1526 |
23384 | SPECC1L | HTA11_696_2000001011 | Human | Colorectum | AD | 3.47e-46 | 8.47e-01 | -0.1464 |
23384 | SPECC1L | HTA11_866_2000001011 | Human | Colorectum | AD | 9.67e-31 | 6.83e-01 | -0.1001 |
23384 | SPECC1L | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.54e-24 | 6.46e-01 | -0.059 |
23384 | SPECC1L | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.75e-16 | 9.04e-01 | -0.1706 |
23384 | SPECC1L | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.71e-10 | 6.78e-01 | -0.2061 |
23384 | SPECC1L | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.22e-05 | 6.23e-01 | -0.1462 |
23384 | SPECC1L | HTA11_546_2000001011 | Human | Colorectum | AD | 5.67e-10 | 5.48e-01 | -0.0842 |
23384 | SPECC1L | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.84e-07 | 4.14e-01 | -0.0179 |
23384 | SPECC1L | HTA11_866_3004761011 | Human | Colorectum | AD | 4.49e-11 | 3.59e-01 | 0.096 |
23384 | SPECC1L | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.32e-04 | 3.56e-01 | 0.0446 |
23384 | SPECC1L | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.79e-02 | 3.40e-01 | 0.0528 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPECC1L | SNV | Missense_Mutation | novel | c.2213N>T | p.Arg738Ile | p.R738I | Q69YQ0 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | novel | c.2981N>C | p.Ile994Thr | p.I994T | Q69YQ0 | protein_coding | deleterious(0) | possibly_damaging(0.697) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | novel | c.187N>A | p.Ala63Thr | p.A63T | Q69YQ0 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | rs774298872 | c.1901N>A | p.Arg634Gln | p.R634Q | Q69YQ0 | protein_coding | tolerated(0.39) | benign(0.02) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SPECC1L | SNV | Missense_Mutation | c.1990N>T | p.Asp664Tyr | p.D664Y | Q69YQ0 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
SPECC1L | SNV | Missense_Mutation | novel | c.2010A>C | p.Glu670Asp | p.E670D | Q69YQ0 | protein_coding | tolerated(0.5) | benign(0.013) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | novel | c.3172N>T | p.Ile1058Phe | p.I1058F | Q69YQ0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DD-AACT-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | c.3293G>T | p.Arg1098Leu | p.R1098L | Q69YQ0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SPECC1L | SNV | Missense_Mutation | novel | c.2219G>T | p.Arg740Leu | p.R740L | Q69YQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
SPECC1L | SNV | Missense_Mutation | c.1142N>T | p.Arg381Leu | p.R381L | Q69YQ0 | protein_coding | tolerated(0.28) | probably_damaging(0.999) | TCGA-44-6778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23384 | SPECC1L | NA | methotrexate | METHOTREXATE | 18539621 |
Page: 1 |